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INCREASED COSTS AFTER ALLOGENEIC HAEMATOPOIETIC SCT ARE AS-
SOCIATED WITH MAJOR COMPLICATIONS AND RE-TRANSPLANTATION
Svahn, B.-M.1, Remberger, M.1, Alvin, O.2, Karlsson, H.1, Ringden, O.1
1Karolinska Institutet Karolinska University Hospital Huddinge, Stock-
holm, Sweden; 2Karolinska Institutet, Stockholm, Sweden
We wanted to evaluate factors associated with high costs after al-
logeneic hematopoietic stem cell transplantation (HSCT). We col-
lected all in-patient and out-patient costs during the first year after
HSCT over five years, from 2003 to 2007. Mean one-year costs per
patient were V141,493 (95% CI 5 125,019 to 157,967). Patients
treated with non-myeloablative conditioning had reduced costs,
but patients treated with reduced-intensity or myeloablative condi-
tioning had similar one-year costs. Multivariate analysis showed
that increased one-year costs were seen in post-transplant complica-
tions: rejection (RH 1.24, p\0.001), acute graft-versus-host disease
(GVHD) of grades III–IV (1.31, p\0.001) and invasive fungal infec-
tion (1.15, p 5 0.02). In addition, increased costs were associated
with re-transplantation (1.21, p 5 0.001), mesenchymal stem-cell
therapy (1.26, p\0.001) unrelated donor transplants (1.20, p 5
0.002), and the need for granulocyte colony-stimulating factor
treatment due to poor engraftment (1.12, p 5 0.047). In patients
without any of these risk factors, mean one-year costs were
V84,773 (95% CI 71,145-98,400) (n 5 51). With three risk factors,
the cost increased toV249,775 (166,824-332,727) (n5 14). To con-
clude, major complications increased the costs of HSCT. Unrelated
donor transplants were more expensive than HLA-identical sibling
transplants. Costs were reduced in patients treated with non-mye-
loablative conditioning.
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RISK FACTORS FOR RELAPSE IN PATIENTS WITH MYELOID
MALIGNANCIES
Uzunel, M.1, Mattsson, J.2, Ljungman, P.3, Ringden, O.2,
Remberger, M.1 1Karolinska University Hospital, Stockholm, Sweden;
2Karolinska University Hospital, Stockholm, Sweden; 3Karolinska Uni-
versity Hospital, Stockholm, Sweden
Background:The past ten years, there has been an increase in using
reduced intensity conditioning regimens (RIC) in allogeneic stem
cell transplantation (SCT) for different diseases. Long term effects
of these conditioning regimens on outcome factors like relapse is
now being investigated in different studies. In this study, we studied
risk factors for relapse in patients with acute myeloid leukemia
(AML) and myelodysplastic syndrome (MDS).
Patients: 267 patients transplanted between 1999 and 2011 were in-
cluded.Most patients had AML (n5 193) and 74 hadMDS. RICwas
given to 92 patients and myeloablative conditioning (MAC) to 175
patients. The RIC regimens consisted mainly of a combination of
Fludarabine and Busulphan.
Results: Four different risk factors for relapse were found in univar-
iate analysis.
(1) Unrelated transplantation (33% relapse incidence at 5 years) vs
sibling transplants (22%), p 5 0.05.
(2) AcuteGVHD, anygrade, (23%) vs no aGVHD(40%), p5 0.02.
(3) RIC (37%) vs MAC (26%), p 5 0.02.
(4) A donor sero-positive for 3-4 herpes viruses (CMV,HSV,VZV
and EBV) was correlated with decreased incidence of relapse (27%),
compared to if the donor was positive for only 0-2 of these viruses
(38%), p 5 0.03.
Higher relapse risk in unrelated donor SCT is partly explained by
the use of ATG in these patients. Especially in unrelated transplants
with RIC, ATG in combination with long immunosuppression may
have hampered the antileukemia effect. In fact, the highest risk of re-
lapse was found in unrelated transplants with RIC (40%).
In sibling transplants, no effect of RIC on relapse was found.
In multivariate analysis, the most significant factor for relapse was
donor virus serology.
Conclusion: In this study, we could find that the use of ATG in un-
related transplants after RIC was correlated with high risk of relapse.
Interestingly, the donor virus serology seems to have an effect on re-
lapse. It may be speculated that donor T-cells with previous virus in-
fections may be more immune reactive. It could also be that virus
specific T-cells may cross-react with leukemia cells.365
REDUCED INTENSITY CONDITIONING WITH PENTOSTATIN AND LOW-
DOSE TBI IN PATIENTS WITH RELAPSED HEMATOLOGIC MALIGNANCIES
Isufi, I.1, Yao, X.2, Seropian, S.1, Cooper, D.1, Shlomchik,W.1, Deng, Y.2,
Barbarotta, L.1, Foss, F.1 1Yale University School of Medicine, New Ha-
ven, CT; 2Yale University, New Haven, CT
Reduced intensity conditioning regimens have been developed
which have resulted in successful engraftment of allogeneic stem
cells with reduced regimen-related toxicities.We previously demon-
strated in a Phase II study that a regimen of extracorporeal photo-
pheresis (ECP), pentostatin (4mg/m2 CIVI days -5 and -4) and
600 cGy of TBI was associated with stable engraftment, a NRM of
11% and a reduced incidence of acute and chronic GVHD. We
now report results from 37 pts with lymphoid malignancies treated
with pentostatin and TBI 600cGy (days -3 and -2) followed by allo-
geneic stem cell infusion. Three pts with T-cell lymphomas who re-
ceived ECP as part of the regimen on days -7 and -6 are included.
Median age was 59yrs (range 20-69). Indications for transplant
were B-NHL (17 pts), B-ALL (6 pts), PTCL (9 pts), CTCL (3
pts) and T-ALL (2 pts). Four pts had prior autologous transplant
and 1 had prior alloBMT for ALL. Based on CIBMTR disease clas-
sification, 68% (15pts) were intermediate or high risk. Donors were
matched related (MRD) in 18 pts, matched unrelated (MUD) in 12,
and mismatched unrelated (MMUD) in 7. Tacrolimus/Mycopheno-
late (Tac/MMF) were used for GVHD prophylaxis in 30 pts with
MRD or MUD, and Tacrolimus/Sirolimus/Methotrexate (Tac/
Rapa) were used in the 7 pts withMMUD. Filgrastrim was routinely
used from day +7 to engraftment in all but 1pt. There were no graft
rejections. The 100-day TRMwas 8%. At a median follow up of 428
days, the median survival has not been reached; 24 (65%) pts are alive
and 92% are in remission. The median overall PFS was 18.2 mo, and
PFS for the int/high risk pts was 16.4 mo. There was no difference in
OS or PFS betweenCIBMTR low and int/high risk groups (p5 0.90
and 0.77 respectively). Of the 8 pts with ALL, 3 relapsed and 5 died
(2 with GVHD). Incidence of acute GVHD grade 3-4 was 11%
(38% for grade 2-4). Extensive chronic GVHD occurred in 11 pts
(30%). Infectious complications included bacteremia in 18 pts,
CMV reactivation in 16 pts, and HHV-6 in 4 pts. There were no
invasive fungal infections. Regimen related toxicities included renal
insufficiency in 4 pts who received Tac/Rapa and 1 pt who received
Tac/MMF. One pt died from TTP (thrombotic microangiopathy)
and DAH (diffuse alveolar hemorrhage). In summary, these results
demonstrate that this regimen of infusional pentostatin and low-dose
TBIwas well tolerated and associated with significant disease control
in both low and high risk patients with lymphoid malignancies.
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ALLOGENEIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE
MYELOID LEUKEMIA: NO INCREASE IN RELAPSE WITH ALEMTUZU-
MAB-DEPLETED GRAFTS
Thomson, K.J.1, Kottaridis, P.2, Cassoni, A.3, Morris, E.C.4, Khwaja, A.4,
Linch, D.C.4, Chakraverty, R.4, Peggs, K.S.4,Mackinnon, S.4 1University
College Hospital, London, United Kingdom; 2Royal Free Hospital, London,
United Kingdom; 3University College Hospital, London, United Kingdom;
4University College London, United Kingdom
The role of T cell depletion in allogeneic stem cell transplantation
for acute myeloid leukemia (AML) remains uncertain. T cell deple-
tion has the capacity to reduceGVHD-related toxicity, an important
issue for the majority of patients requiring a transplant who do not
have an HLA-matched related donor available, but there are con-
cerns about a potential reciprocal increase in relapse risk. This study
describes the results in 56 consecutive adults with high-risk AML
transplanted with an alemtuzumab-containing myeloablative regi-
men, which provides partial T cell depletion, using HLA-matched
or mismatched unrelated donors.
AML developed de novo in 50 patients (89%) and was secondary
in 6 (3 transformedMDS; 3 therapy-related AML). All patients were
high-risk for relapse, as defined by induction failure, adverse cytoge-
netics (-5, -7, del(5q), abnormal 3q or complex5.4 abnormalities),
.CR1, or secondary disease. 13/56 (23%) had refractory disease at
transplant. The median age at transplant was 36 years (16-57) and
22 (39%) donors were HLA-mismatched at#3/10 loci (12 x1 locus,
9 x2, 1 x3). Patients received fludarabine 30mg/m2/day D–9 to -7,
S340 Poster Session IIcyclophosphamide 60 mg/kg/day D-6 to -5, and 14.4Gy total body
irradiation in 8 fractions D–3 to 0, with 20mg alemtuzumab added
to the bag in vitro, and cyclosporin as GVHD prophylaxis.
Median follow-up for surviving patients was 52 months. All pa-
tients engrafted, at a median of 11 days for neutrophils and 10 days
for platelets. Acute GvHD grade II-IV occurred in 16% (3/9 grade
.II) and extensive chronic GvHD in 27%, which was cutaneous
only in 10/13, and responded to prolonged cyclosporin alone or
short course systemic corticosteroid. Non-relapse mortality
(NRM)was 23% at 5 years, and estimated relapse risk 26%at 5 years.
Estimated event-free survival (EFS) was 54% at 5 years. Complete
remission at the time of transplant and the presence of any chronic
GVHD favourably impacted EFS, with HLA mismatching confer-
ring no disadvantage.
Use of this regimen therefore permits the successful transplanta-
tion of patients with high-risk disease using unrelated donors, with
no negative impact of HLA-mismatching at one and two loci (12
and 9 patients respectively), minimal acute GvHD, a modest rate
of chronicGVHDwhich was largely confined to skin and was readily
treatment-responsive, and no evidence of an excessive relapse rate.
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IMPACT OF A LOWER BUSULFAN AREA UNDER THE CONCENTRATION-
TIME CURVE (AUC) DOSING TARGET ON ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) OUTCOMES
CruzChacon, A.M.1, Perkins, J.B.1, Pidala, J.A.1, Kim, J.2, Yue, B.2,
Field, T.1, Anasetti, C.1 1Moffitt Cancer Center, Tampa, FL; 2Moffitt
Cancer Center, Tampa, FL
Busulfan systemic exposure, as measured pharmacokinetically by
area under the concentration-time curve (AUC), has been correlated
with transplant-related toxicity and efficacy. Attempting to reduce
morbidity and mortality in patients (pts) 60 years (yrs) or older
and/or those with significant comorbidity, we have pharmacokineti-
cally-targeted a lower daily busulfan AUC of 3500 mmol x min/L
compared to 5300 used in other pts. To evaluate the effectiveness
of this strategy, we retrospectively compared outcomes in 345 con-
secutive pts with hematologic malignancies receiving busulfan and
fludarabine from 7/04-10/09. 44 pts were targeted to busulfan
AUC of 3500 and were more likely to receive a matched unrelated
graft (p 5 0.038), have CLL, indolent NHL, or MDS (p\0.0001)
and a high risk of relapse as defined by CIBMTR criteria
(p\0.0001) compared to the AUC 5300 cohort. The median age
was 62 yrs for the AUC 3500 pts and 48 yrs for AUC 5300 pts
(p\0.0001). There were no significant differences in CMV serology,
HCT-CI scores, Karnofsky performance status (KPS), or history of
prior transplant. When adjusted for CMV serology, donor, diagno-
sis, HCT-CI, KPS, and age, busulfan AUCwas not a significant pre-
dictor of overall survival or cumulative incidence of nonrelapse
mortality. However, busulfan was an independent factor in a multi-
variable model for relapse-free survival (RFS) (HR 1.67; 95% CI
1.13-2.48) and of borderline significance in a multivariable model
of cumulative incidence of relapse (HR 1.7; 95%CI 0.98-2.93).
The 2-year estimate of RFS in the AUC 3500 pts was 21.9% vs
44.1% in the AUC 5300 pts. The cumulative incidence of relapse
at 2 years in the AUC 3500 was 41% vs. 31% in the AUC 5300
pts. This would suggest that careful consideration should be made
in choosing to reduce busulfan AUC as a reduction in intensity
may lead to reduced efficacy. These results should be interpreted
with caution due to the limitations of multivariable analysis of retro-
spective data as other patient characteristics may exist that cannot be
accounted for in this type of analysis.
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FLUDARABINE BASED PREPARATIVE REGIMEN CAN SECURE A SECOND
HEMATOPOIETIC STEM CELL TRANSPLANT AFTER INITIAL GRAFT REJEC-
TION
Tamari, R.1, Boulad, F.2, Papadopoulos, E.B.1, Kernan, N.A.2,
Jakubowski, A.1, Small, T.N.2, Perales, M.A.1, O’Reilly, R.J.2,
Young, J.W.1, Giralt, S.1, Barker, J.1, Castro Malaspina, H.1 1Memorial
Sloan Kettering Cancer Center, New York, NY; 2Memorial Sloan Ketter-
ing Cancer Center, New York, NY
Graft rejection after allogeneic stem cell transplantation (HSCT)
is a rare but often fatal complication.The optimal preparative regi-men for engraftment of a second transplant has not been well de-
fined. We previously described our experience in HSCT-2 for
graft rejection in 16 pts, we report here a larger series.
Patients&Methods:From1997- 2010, 24 pts underwent aHSCT-
2 for graft rejection. Median age was 19.8 years (range: 1- 61). All pts
were conditioned for HSCT-1 with myeloablative preparative regi-
men (TBI or busulfan-based) for acute chronic leukemia (N5 11/2),
MDS (N5 7) or congenital hematopoietic non-malignant disorders
(N 5 4). 20 of the first transplants were TCD. The donors for the
first transplant were: HLA matched related/unrelated (N 5 4/6),
HLA mismatched related/unrelated (N 5 3/11).The preparative
regimen for the second transplant consisted of Fludarabine (Flu)
(30 mg/m2/d/5 days) plus Cyclophosphamide (Cy) (60 mg/kg/d/2
days) (N 5 13), Flu (25 mg/m2d/ 5 days) plus Thiotepa (5 mg/kg/
d/2 days) (N 5 5), Cy (60 mg/kg/d/2 days) plus Thiotepa (5 mg/
kg/d/2 days) (N 5 3), Flu (30 mg/m2d/5 days) (N 5 2), Cy plus
low dose TBI (N 5 1). Thus, 19 of the 24 pts (79%) were condi-
tioned for HSCT-2 with a Flu based regimen. Pts also received
ATG (N 5 19) or Campath (N 5 5). The donors for HSCT-2
were: HLA-matched related/unrelated (N5 4/3), HLAmismatched
related/unrelated (N 5 10/7). The original donor was used in 8/24
cases. The grafts administrated were unmodified PBSCT (N 5 8),
unmodified BMT(N 5 2) or TCD PBSCT (N 5 14). The median
CD34/kg infused in the second transplant was 11.8x106CD34/kg
(2.8-34x106CD34/kg).
Results:All pts engrafted with a median of 13 (9-26) days; full donor
engraftment was documented in 21 (88%) pts. GVHD developed in
8 (33%) pts (aGvHD-7, cGvHD-1), 3 had received a TCD graft and
5 an unmodified graft. CMV and EBV reactivations occurred in 6
(25%) patients with 2 cases of EBV-LPD and 1 case of CMV pneu-
monitis. The preparative regimen for the second transplant was well
tolerated with minimal mucositis, and only one serious adverse
event: veno-occlusive disease. Twelve pts (50%) are alive with a me-
dian follow up time of 9.75 years (1.75-13.5 years); 9 pts (64%) re-
ceived a TCD transplant and 3 pts (30%) an unmodified transplant.
Conclusion: In this cohort of pts who underwent a HSCT-2, either
unmodified or TCD, Flu based chemotherapy conditioning was able
to assure engraftment with a relatively low toxicity profile and long
term survival.
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OUTCOMES OF SECOND TRANSPLANTS FOR DISEASE RECURRENCE OR
FOR MYELODYSPLASIA (MDS) DEVELOPING AFTER AN INITIAL TRANS-
PLANT (Tx)
Naik, S., D’Agostino, R. Jr., Lamar, Z., Graham, R.M., Vatca, M.,
Agnew, E., Higgins, A., Levitan, D., Hurd, D.Wake Forest Baptist Med-
ical center, Winston-Salem, NC
Introduction: Treatment options for persons who relapse after an
initial transplant (autologous [AutoTx] or allogeneic [AlloTx]) or
who develop MDS following an AutoTx are limited. Current treat-
ment options include chemotherapy, donor leukocyte infusions
(DLI) (if alloTx) and a second transplant. A second transplant may
be effective salvage therapy in some patients (pts) who relapse or
who develop MDS after their initial Tx if an allo donor can be
identified.
Methods: A total of 1808 transplants were performed at Wake For-
est Baptist Hospital from May 1990 through July 2011 and 1525 Tx
(84%) were performed for diagnosis of a hematological malignancy.
Of these, 52 pts (3%) received a second Tx for disease recurrence or
therapy relatedMDS.The diagnosis at the time of first transplant in-
cluded acute and chronic leukemia (n 5 15); lymphoma (n 5 16);
myeloma (n 5 16); MDS: MF (n 5 4(3:1)); germ cell tumor (n 5
1). An additional 7 pts who received second transplant were excluded
from analysis (1: aplastic anemia pt; 5 for planned tandem AutoTx;
one for insufficient data. Transplants were either Auto / Auto
(for relapse; n 5 12); Allo/ Allo (for relapse; n 5 9); or Auto/
Allo (for relapse or the development of MDS; n 5 31).
Results: Patient characteristics are presented in Table 1.PB (pe-
ripheral blood) was the most common graft type in 43 pts (n5 83%).
Median time to second transplant was 1.8 years (0.27-18 yrs). Total
body irradiation (TBI) was given in 17 % (n 5 9) pts during first
transplant and 6 % (n 5 3) pts during second transplant. Reduc-
ed-intensity regimen (Flu/Bu) was used in 42 % (n 5 22) pts and
myeloablative Bu/Cy regimen in 25 % (n 5 13) pts during second
